ReviewOphthalmology and therapy2023
Ophthalmic Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review.
Review in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The Efficacy of Sutureless Amnion Membrane Transplantation for Corneal Epithelialization in Delayed Corneal Healing: A Systematic Review.Korean journal of ophthalmology : KJO · 2025Pooled it
- Diagnosis and Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Patients: A Systematic Review of Clinical Guidelines and Consensus Statements.Pediatric dermatologyPooled it
- Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap With Severe Ocular and Oral Involvement: A Pediatric Case Report From Uganda.Clinical case reports · 2026Article
- Ocular involvement in toxic epidermal necrolysis syndrome at Chelsea and Westminster Hospital: a 10-year retrospective analysis and review of current literature.Eye (London, England) · 2026Review
- Seen on screen, missed in clinic: educational pearls fromSkin health and disease · 2026Review
- A Rare Case of Stevens-Johnson Syndrome Secondary to Levofloxacin Administration: Presentation and Management.Cureus · 2026Article
- The Multiorgan Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review.Clinical, cosmetic and investigational dermatology · 2026Review
- Ocular administration of brinzolamide leading to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap: A case report and review.Medicine · 2025Review
- Inhibition of formyl peptide receptor-1-mediated cell death as a therapy for lethal cutaneous drug reactions in preclinical models.Nature communications · 2025Article
- Mycoplasma-Induced Rash and Mucositis: Ocular Manifestations, Treatment and Outcomes in a Paediatric Population.Journal of paediatrics and child health · 2025Article
- A Narrative Review of Amniotic Membrane Transplantation in Ocular Surface Repair: Unveiling the Immunoregulatory Pathways for Timely Intervention.Ophthalmology and therapy · 2025Review
- Conjunctival squamous metaplasia on amniotic membrane in Stevens-Johnson syndrome: a case report.BMC ophthalmology · 2024Article
- Eyelid Reconstruction.Seminars in plastic surgery · 2024Review
- The outcomes of corneal sight rehabilitating surgery in Stevens-Johnson syndrome: case series.BMC ophthalmology · 2024Article
- Clinical Characteristics and Treatment of Ophthalmic Sequelae of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at a Tertiary Eyecare Centre in Hungary.Ophthalmology and therapy · 2024Article
- Updates in SJS/TEN: collaboration, innovation, and community.Frontiers in medicine · 2023Review
- Restoring the mucin barrier: Advances in secretagogue therapies for ocular surface disorders.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
The aim of our review article was to summarize the current literature on Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN). SJS/TEN is a serious, rare multi-system, immune-mediated, mucocutaneous disease with a significant mortality rate that can lead to severe ocular surface sequelae and even to bilateral blindness. Restoration of the ocular surface in acute and chronic SJS/TEN is challenging. There are only limited local or systemic treatment options for SJS/TEN. Early diagnosis, timely amniotic membrane transplantation and aggressive topical management in acute SJS/TEN are necessary to prevent long-term, chronic ocular complications. Although the primary aim of acute care is to save the life of the patient, ophthalmologists should regularly examine patients already in the acute phase, which should also be followed by systematic ophthalmic examination in the chronic phase. Herein, we summarize actual knowledge on the epidemiology, aetiology, pathology, clinical appearance and treatment of SJS/TEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.